Core Viewpoint - The company reported a mixed performance for 2024 and Q1 2025, with revenue growth in 2024 but a decline in Q1 2025, while maintaining a positive outlook due to domestic market opportunities arising from government policies [1][5]. Group 1: Financial Performance - In 2024, the company achieved revenue of 30.13 billion yuan, with a year-on-year growth of 3.48%, while net profit attributable to shareholders was -6.01 billion yuan [1]. - Q4 2024 saw significant revenue growth of 61.6% year-on-year, reaching 11.43 billion yuan [1]. - For Q1 2025, revenue declined by 14.3% year-on-year to 4.55 billion yuan, with net profit at -1.33 billion yuan [1]. Group 2: Business Segments - The gene sequencing business generated revenue of 23.48 billion yuan in 2024, reflecting a 2.5% year-on-year increase, with instrument revenue at 9.60 billion yuan (+6.9% year-on-year) and reagent revenue at 13.73 billion yuan (+1.4% year-on-year) [2]. - The laboratory automation segment reported revenue of 2.09 billion yuan, with over 500 new installations, indicating a shift away from pandemic-related demand [2]. - New business revenue reached 4.0 billion yuan, excluding pandemic-related income, marking a 57.1% year-on-year increase, with single-cell related revenue growing by 172.0% [2]. Group 3: Market Position and Outlook - The domestic gene sequencing business performed well in 2024, with revenue of 16.07 billion yuan (+11.4% year-on-year) and a market share of 63.8% in new installations [3]. - The overseas segment faced challenges, with a revenue decline of 12.7% year-on-year to 7.41 billion yuan, but opportunities for growth exist due to competitive pricing and channel advantages [3]. Group 4: Cost Management and Profitability - The company's gross margin improved to 55.9% in 2024, with specific margins for gene sequencing, laboratory automation, and new businesses at 60.3%, 44.4%, and 35.5% respectively [4]. - R&D expenses decreased by 18.0% year-on-year to 7.46 billion yuan in 2024, while sales and management expenses increased [4]. - In Q1 2025, sales, management, and R&D expenses decreased by 10.5%, 9.2%, and 32.8% year-on-year respectively [4]. Group 5: Revenue Forecast and Valuation - Revenue projections for 2025-2027 have been adjusted to 36.65 billion yuan, 46.91 billion yuan, and 51.47 billion yuan, reflecting an 11% downward revision for 2025 and 2026 [5]. - The company is positioned as a leading domestic player in the gene sequencing equipment sector, with a target price of 88.0 yuan for 2025, based on a 10x price-to-sales ratio [5].

Core Insights - The company reported a revenue of 3.013 billion yuan for 2024, marking a year-on-year growth of 3.48% [1] - The core gene sequencing instrument business generated revenue of 2.348 billion yuan, with a year-on-year increase of 2.47% [1] - The company showed resilience in a competitive global landscape, with a nearly 34% reduction in net profit loss year-on-year in the first quarter [1] Financial Performance - The domestic gene sequencing instrument revenue reached 1.607 billion yuan, reflecting an 11.37% year-on-year growth [1] - The first quarter saw a significant reduction in sales, management, and research expenses, which collectively decreased by 19% year-on-year [1] - The company achieved a 48.59% year-on-year increase in new sales installations of gene sequencing instruments globally [1] Market Position - The company maintained its position as the leader in new installations in the domestic market for three consecutive years, with a market share of 63.8% in 2024 [1] - The global market share for new installations increased by 9.5 percentage points to 28.2% compared to 2023 [1] Technological Advancements - The company has achieved a comprehensive strategic layout for three technical pathways in gene sequencing products, becoming the first globally to have large-scale commercial production of both short-read and long-read sequencing products [2] - Revenue from cell genomics increased by 171.98% year-on-year, with a nearly threefold growth in the Asia-Pacific region [2] - The integration of AI, biotechnology, and information technology has led to the deployment of AI models in the new Alpha Cube, supporting high-throughput sequencing needs [2] Industry Outlook - The company is expected to strengthen its leading position in the industry due to accelerated support from national policies and its self-controlled technology and supply chain systems [2] - The company is penetrating emerging scenarios such as clinical applications, disease control, environmental ecology, and agricultural breeding through continuous core technology research and multi-scenario applications [2]